Compare STEL & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STEL | TMDX |
|---|---|---|
| Founded | 2007 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.2B |
| IPO Year | 2017 | 2019 |
| Metric | STEL | TMDX |
|---|---|---|
| Price | $37.33 | $68.69 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | $37.00 | ★ $148.22 |
| AVG Volume (30 Days) | 211.7K | ★ 1.8M |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.61% | N/A |
| EPS Growth | N/A | ★ 382.18 |
| EPS | ★ 0.53 | 0.20 |
| Revenue | $6,282,000.00 | ★ $605,494,000.00 |
| Revenue This Year | $10.14 | $24.25 |
| Revenue Next Year | $4.65 | $18.75 |
| P/E Ratio | ★ $69.40 | $337.65 |
| Revenue Growth | N/A | ★ 37.13 |
| 52 Week Low | $26.30 | $60.11 |
| 52 Week High | $40.21 | $156.00 |
| Indicator | STEL | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 51.33 | 35.63 |
| Support Level | $36.95 | $60.11 |
| Resistance Level | $38.02 | $71.14 |
| Average True Range (ATR) | 0.50 | 3.80 |
| MACD | 0.00 | 1.63 |
| Stochastic Oscillator | 69.94 | 79.97 |
Stellar Bancorp Inc is a U.S. based bank holding company. Through its subsidiary, Stellar Bank, the company provides a diversified range of commercial banking services predominantly to small to medium sized businesses, professionals, and individual customers. Its offerings include different types of loans, such as mortgage loans, home equity loans, automobile loans, etc.; deposit products, such as checking accounts, commercial accounts, money market accounts, savings accounts, etc. and other banking services like mobile banking, debit cards, cash management and wire transfer services, letters of credit, and others.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.